Post Partum Hemorrhage Clinical Trial
Official title:
Comparison Between Adjunctive Sublingual Misoprostol Versus Adjunctive Placebo in the Reduction of Intraoperative Blood Loss During Caesarean Section
Caesarean delivery is inevitably associated with a higher amount of blood loss vis-à-vis primary postpartum haemorrhage, when compared to vaginal delivery. Oxytocin use in tropical developing countries for the reduction blood loss at caesarean section have been met with challenges of ineffectiveness due to poor transportation, inadequate storage and drug adulteration. Therefore, there is a need for an effective, temperature stable uterotonic with a lesser risk of adulteration. The study is aimed at evaluating the effectiveness and safety of adjunctive sublingual misoprostol in reducing intraoperative blood loss at caesarean section.
It would be a double blind randomized controlled trial. One hundred and fifty-two pregnant women at term who have indications for caesarean section and have risk factors for primary postpartum haemorrhage, as well as meet the eligibility criteria would be randomized equally into two study arms (Misoprostol study arm and Placebo study arm) after informed consent. The Misoprostol study arm will receive 400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets. The Placebo study arm would receive two sublingual placebo tablets similar to the misoprostol tablets. The Misoprostol and the Placebo tablets will be given in each study arm at the point of starting the uterine incision at caesarean section. Both study arms would receive routine intravenous oxytocin at the time of clamping of the umbilical cord. The outcome measures will be estimated intraoperative blood loss, the need for additional intraoperative oxytocic, blood transfusion, the occurrence of side effects, and incidence of primary postpartum haemorrhage. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03680339 -
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
|
Phase 4 | |
Completed |
NCT03693599 -
Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean
|
Phase 4 | |
Completed |
NCT03707132 -
Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
|
||
Recruiting |
NCT02306733 -
Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally
|
Phase 3 | |
Completed |
NCT01866241 -
Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage
|
Phase 3 | |
Not yet recruiting |
NCT01236482 -
Oxytocin in Cesarean Delivery
|
Phase 4 | |
Completed |
NCT03784794 -
Patient Blood Management for Massive Obstetric Hemorrhage
|
N/A | |
Enrolling by invitation |
NCT06255496 -
QStat Cartridge in Obstetric Patients
|
||
Recruiting |
NCT04401839 -
Amr Maneuver for Prevention of Postpartum Hemorrhage
|
N/A | |
Recruiting |
NCT06219538 -
DAISY Uterine Drain Device Evaluation
|
N/A | |
Not yet recruiting |
NCT06333340 -
Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery
|
N/A | |
Completed |
NCT01863706 -
Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage
|
Phase 1 | |
Completed |
NCT04723979 -
NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL
|
||
Terminated |
NCT04277962 -
Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial
|
N/A | |
Completed |
NCT03570723 -
Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa
|
N/A | |
Completed |
NCT03117647 -
Mansoura-VV Uterine Compression Suture for Primary Atonic Postpartum Hemorrhage
|
N/A | |
Active, not recruiting |
NCT03069859 -
Use of TXA to Prevent Postpartum Hemorrhage
|
Phase 2 | |
Not yet recruiting |
NCT03891082 -
A Comparative Study Between Bakri Balloon and B Lynch Suture Used to Control Primary Postpartum Hemorrhage After Cesarean Section
|
N/A | |
Not yet recruiting |
NCT03463070 -
Misoprostol Before and After Cesarean Section
|
Phase 3 | |
Completed |
NCT03907605 -
Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Ligation for Postpartum Hemorrage (PPH)
|